[Long noncoding RNA H19 promotes vascular calcification by repressing the Bax inhibitor 1/optic atrophy 1 pathway]

Nan Fang Yi Ke Da Xue Xue Bao. 2023 Sep 20;43(9):1469-1475. doi: 10.12122/j.issn.1673-4254.2023.09.03.
[Article in Chinese]

Abstract

Objective: To investigate whether long noncoding RNA H19 (lncRNA H19) induces vascular calcification by promoting calcium deposition, osteogenic differentiation and apoptosis via inhibiting the Bax inhibitor 1/optic atrophy 1 (BI-1/ OPA1) pathway.

Methods: β-glycerophosphate and calcium chloride were used to induce calcification in rat vascular smooth muscle cells (VSMCs), and the effects of siH19, alone or in combination with BI-1 or OPA1 knockdown, on calcification of the cells were investigated. Osteogenic differentiation was assessed by measuring Runt-related transcription factor 2 (Runx-2) and bone morphogenetic protein 2 (BMP-2) expression with Western blotting, and cell apoptosis was evaluated by TUNEL staining and Western blotting. An ApoE-/- diabetic mouse model with high-fat feeding for 32 weeks were given an intraperitoneal injection of siH19, and the changes in calcium deposition in the aortic arch were examined using Alizarin red S staining and von Kossa staining.

Results: In rat VSMCs with calcification, the expression of lncRNA H19 was significantly increased, and the expressions of BI- 1 and OPA1 were significantly decreased. Downregulation of lncRNA H19 significantly increased the expressions of BI-1 and OPA1 proteins in the cells, and BI-1 knockdown further reduced OPA1 expression (P<0.001). The cells treated with siH19 showed total disappearance of the calcified nodules with significantly reduced expressions of Runx-2, BMP-2 and cleaved caspase-3 and a lowered cell apoptosis rate (P<0.001). Calcified nodules were again observed in the cells with lncRNA H19 knockdown combined with BI-1 or OPA1 knockdown, and the expressions of Runx-2, BMP-2, cleaved-caspase-3 and cell apoptosis rate all significantly increased (P<0.001). In the diabetic mouse model with high-fat feeding, siH19 treatment significantly reduced the calcification area and increased mRNA expressions of BI-I and OPA1 in the aortic arch.

Conclusion: LncRNA H19 promotes vascular calcification possibly by promoting calcium deposition, osteogenic differentiation and cell apoptosis via inhibiting the BI-1/OPA1 pathway.

目的: 探讨长链非编码RNA H19(lncRNA H19)是否通过抑制Bax抑制因子1/视神经萎缩蛋白1(BI-1/OPA1)通路促进钙沉积、细胞骨型分化和细胞凋亡,进而诱导血管钙化。

方法: β磷酸甘油和氯化钙药物诱导大鼠血管平滑肌细胞(VSMC)建立细胞钙化模型,将细胞分为5组:对照组(普通培养基培养14 d)、钙化组(钙化培养基培养14 d)、钙化+siH19组(敲低lncRNA H19表达后钙化培养基培养14 d)、钙化+siH19+BI-1-/-组(敲低lncRNA H19和BI-1表达后钙化培养基培养14 d)和钙化+siH19+ OPA1-/-组(敲低lncRNA H19和OPA1表达后钙化培养基培养14 d)。另ApoE-/-糖尿病小鼠使用高脂饲料喂养32周建立动物钙化模型。通过茜素红S染色和von Kossa染色检测钙沉积,通过Western blotting测定Runt相关转录因子2(Runx-2)、骨形态发生蛋白2(BMP-2)观察细胞骨型分化,通过TUNEL染色和半胱氨酸天冬氨酸蛋白酶3检测观察细胞凋亡情况。

结果: 血管钙化后,lncRNA H19表达明显上升,BI-1和OPA1表达明显下降,而siRNA敲低lncRNA H19表达后,BI-1和OPA1蛋白表达明显上升;抑制BI-1后,OPA1再次下降(P<0.001)。siRNA敲低lncRNA H19表达后,钙化结节消失,钙含量、Runx-2、BMP-2、活化半胱氨酸天冬氨酸蛋白酶3表达和细胞凋亡率均显著降低(P<0.001)。siRNA敲低lncRNA H19基础上再抑制BI-1或OPA1蛋白,钙化结节出现,钙含量、Runx-2、BMP-2、活化半胱氨酸天冬氨酸蛋白酶3表达和细胞凋亡率均显著增加(P<0.001)。

结论: LncRNA H19通过抑制BI-1/OPA1蛋白通路诱导血管钙化,其可能机制和促进钙沉积、细胞骨型分化和细胞凋亡有关。

Keywords: Bax inhibitor 1; long noncoding RNA H19; optic atrophy 1; osteogenic differentiation; vascular calcification.

Publication types

  • English Abstract

MeSH terms

  • Animals
  • Calcium / metabolism
  • Caspase 3 / metabolism
  • Cells, Cultured
  • Diabetes Mellitus* / metabolism
  • Disease Models, Animal
  • Mice
  • Myocytes, Smooth Muscle
  • Optic Atrophy, Autosomal Dominant* / metabolism
  • Osteogenesis
  • RNA, Long Noncoding* / genetics
  • RNA, Long Noncoding* / metabolism
  • Rats
  • Vascular Calcification* / metabolism
  • bcl-2-Associated X Protein / metabolism

Substances

  • bcl-2-Associated X Protein
  • Calcium
  • Caspase 3
  • RNA, Long Noncoding
  • Opa1 protein, rat
  • Opa1 protein, mouse
  • H19 long non-coding RNA
  • Tmbim6 protein, mouse
  • Tmbim6 protein, rat

Grants and funding

国家重点研发计划“精准医学研究”重点专项(2017YFC0908800);国家自然科学基金(82070293);北京市医院管理局“使命”计划专项经费资助(SML20180601);首都卫生发展科研专项(首发2020-2-2063);北京市教育委员会科技计划(KM200910025012);北京市自然科学基金(7202041);北京市博士后资助项目(2020-zz-011)